INVEST IN MAKANI SCIENCE TODAY!
The Makani Science Respiration Monitor uses a completely novel sensor technology, unlike current monitors, and has the potential to become the new standard of care for this vital sign.
Our unique sensor has the potential to make breathing monitoring more accessible in many different wearable applications, tapping into lucrative multi-billion dollar markets increasing at a CAGR of 18.5% fueled by the rise of telehealth.*
Clinicians, potential strategic partners, and researchers have already expressed interest in our product and are excited by our technology and how it can improve the state of the industry.
*The above is a product still currently under development and is not yet available on the market.
The Makani Science Respiratory Monitor was developed to improve respiratory monitoring by making it:
We plan submit our premarket notification to the FDA early 2023 and hope to launch our product Q3 2023. We will target three major areas that would benefit from better respiratory monitoring:
Makani Science is in the process of finalizing a licensing agreement with UC Irvine for the exclusive license to use their family of seven patents around the core sensor technology for monitoring breathing. Makani Science would be able to sublicense the technology, and payments and royalties would be made based on set milestones. UC Irvine would receive a small equity stake in Makani Science.
The Problem & Our solution
It only takes 4 minutes for brain damage to occur after you stop breathing; death is almost guaranteed after 10 minutes. This means every second counts when a patient stops breathing.
It is a shocking reality that in the clinical setting, a vital sign as important as respiration is often poorly monitored. Breath rate is a neglected vital sign, mostly because current monitors, such as pulse oximetry and capnography, are inconvenient, bulky, inaccurate, or have delayed response times (Source | Source | Source). This has been a contributing factor to repeated, potentially preventable, patient complications every year. Outside of the hospital, there are very few wearable technologies that can measure breathing accurately, making this a vital sign relatively untapped.
Makani Science novel sensor component
Due to the unique features of the Makani Science sensor technology – novel, compact, postage-sized, and flexible – shown above, the Makani Science monitoring system overcomes these deficiencies, allowing for direct monitoring of breathing in a more accurate, convenient, and comfortable way.
We believe that because of our unique sensor design and small form factor, the Makani Science Respiration Monitor has the potential to help improve the current state of the art in respiration monitoring and unlock breathing applications never before realized.
The animations above show the convenience of the Makani Science Respiration System, wireless and convenient. The product is still currently under development and is not yet available on the market.
the market & Our Traction
Our initial market will target procedures where patients are sedated, and their breathing may be at risk. Surprisingly, anesthesiologists are not always present to monitor these patients, and sadly, deaths have been repeatedly attributed to improper respiratory monitoring (Source).
For this application, we believe the Makani Science Respiration Monitor can improve the safety of the patients and function as an early alert system for breathing abnormalities. This global anesthesia and respiratory device market is predicted to reach $38.2 billion by 2023 (Source).
Another critical area where the Makani Science Respiration Monitor could disrupt the market is in the disease management sector. There are many diseases that affect our breathing such as COPD, asthma, sleep apnea, and more recently COVID – to name a few.
Responding quickly to changes in the patient's condition is essential for their health. The Makani Science Respiration Monitor could potentially track and manage patient breathing, improving their quality of life. The respiratory device for disease management market is predicted to reach $21.6 Billion by 2023 (Source).
Wellness and Mindfullness
In addition, the wellness, mindfulness, and fitness market have enormous potential for our sensor. As stress and anxiety increase in our society, we believe people will want to start managing their mental health through biofeedback and proper breathing control.
We believe our sensor, in conjunction with the right App, will be the perfect platform to provide information to the user on how well they are breathing to optimize stress reduction (Source | Source). The consumer health and wellness market is predicted to reach $55.8 Billion by 2023 (Source).
*The product is still currently under development and is not yet available on the market.
Due to its differentiating features of being small, flexible, and comfortable, the Makani Science sensor is suitable for wear in clinical settings or home use and can be incorporated into other sensors as well. In total, the potential market for all targeted areas could be over $100 Billion in 2023!
Our Traction and Testimonials
Makani Science has also been accepted into well-known accelerators including Y-Combinator and MedTech Innovators.
*The above testimonials may not be representative of the opinions of other medical experts or the experiences of other customers and is not a guarantee of future performance or success.
*The product is still currently under development and is not yet available on the market.
Whether making sedated procedures safer, managing respiratory diseases, and potentially saving lives, the Makani Science Respiration Monitor can make a neglected vital sign more accessible to the world.
With numerous applications for our product, we are presented with an opportunity to tap into this large multi-billion dollar space and can elevate it to new levels with the Makani Science Respiration Monitor, while saving and improving patient lives.
Join the movement toward better breathing and better health and invest in Makani Science today.
After you stop breathing, it only takes 4 minutes for permanent brain damage to start. Surprisingly, this critical vital sign is poorly monitored, using bulky, wired systems based on technology conceived half a century ago. Makani Science’s novel, compact, and wireless system is poised to bring breathing monitoring to new heights, making this neglected vital sign easier to measure, and unlocking a multi-billion-dollar market. We are currently pre-revenue, pre-FDA clearance and our product is in pre-production.
Michael has worked closely with the Makani Science team from day one to develop the Makani Science Respiratory Monitoring System. He has also actively participated in the business development side of the company, establishing partnerships for future collaborations and research opportunities.
Michael participated in Y-Combinator and MedTech Innovator as part of their 2021 summer cohort where he helped raised additional funding for the company. In Q4 of 2021, Michael was selected as the full time CEO for Makani Science.
Ray has a 30+ year track record of successful business execution and of being a startup queen/kingmaker. Ray has personally made over 300 investments and is well-known for rewarding shareholders with exceptional financial returns.
As the co-founder of Koa Accel and Managing Director of the Koa Accel Venture Fund, Ray is excited to combine all of his expertise and passions to transform life-saving MedTech ideas into thriving commercial ventures.
Greg was a founding executive for CalOptima, a public managed care organization where he served as Chief Operating Officer and Medical Director. He began his professional career as a pioneer in Pediatric Emergency Medicine. His previous positions include work as a Principal Consultant with Health Management Associates, a national healthcare consulting firm. Greg started his career as a Pediatric Emergency Physician serving in leadership positions at two children’s hospitals and as administrative director of a medical group.
He is a Fellow of the American College of Emergency Physicians and American Academy of Pediatrics. Greg has a passion for innovation, the expanded use of technology in healthcare, improving quality of care and heath equity.
CFO (Chief Financial Officer)
He has successfully built and led finance teams with Del Monte Foods and Safeway, Inc. His passion for building financial operations from the ground up has led him from his recent start-up experiences to KOA ACCEL. Stephen’s expertise in economic analysis, strategic planning, and financial modeling has been instrumental to the successful launches of various new products domestically and internationally. He is also highly skilled in developing business processes, systems, and building financial/accounting infrastructure.
Stephen received his MBA degree from Southern Illinois University and both his B.S. degrees in Finance and Marketing from the University of Illinois at Urbana-Champaign
Head of Marketing
She has played an integral part in the growth of large established companies, such as Pfizer (Shiley), Medtronic, Beckman-Coulter, St. Jude Medical, Thermo-Fischer, and most recently Arlene has focused on building the identity, value and infrastructure of many start-ups including EP Dynamics, Reviticell, Pegasus Biologics, PhageTech, BioMedGPS, and TinyKicks. Her consulting company, Silvergleid and Associates, has performed market due diligence for IPOs and advised international companies on the suitability for US market entry.
Arlene holds a BS in Chemistry and Biology from Simmons College and MBA courses from Boston University.
Head of Engineering
Stephane has been working in the medical device Industry for over 25 years; he started in large cap , high-volume corporations (Boston Scientific, Novartis) to gradually focus onto the start-up world and develop his entrepreneurial business sense. He held various technical positions of increasing responsibilities and oversaw the development of several devices from concept definition to FDA clearance and market launch. He transitioned into executive management almost 15 years ago: leading technical teams, interacting with agencies, and helping with Venture Capital fund raising.
Scientific Co-Founder & Director
Maximum Number of Shares Offered subject to adjustment for bonus shares
Most Recent Fiscal Year-End
Prior Fiscal Year-End
Cash & Cash Equivalents
Revenue & Sales
Costs of Goods Sold
Makani Science Inc.
5270 California Ave Ste 300, Irvine, CA 92617
Minimum Investment Amount
Minimum Number of Shares Offered
Maximum Number of Shares Offered
Price per Share
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing; provided, however, that the CEO’s ability to exercise the foregoing powers shall be conditioned upon the unanimous approval of the Board of Directors of the Company. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Friends and Family - First 7 days | 10% bonus shares
Super Early Bird - First 30 days | 5% bonus shares
Tier 1 Perk — Invest $500+ and receive 2% bonus shares
Tier 2 Perk — Invest $1000+ and receive 5% bonus shares
Tier 3 Perk — Invest $5,000+ and receive 10% bonus shares
Tier 4 Perk — Invest $10,000+ and receive 15% bonus shares
Tier 5 Perk — Invest $20,000+ and receive 20% bonus shares
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
Makani Science will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any Common Stock shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.67 / share, you will receive 110 shares, meaning you'll own 110 shares for $67. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
We will not incur any irregular use of proceeds.
Whether it's making sedated procedures safer, managing respiratory diseases, or potentially saving lives, the Makani Science Respiration Monitor can make a neglected vital sign more accessible to the world.
Invest Today! Join the movement toward better breathing.
We are excited to announce that we've been selected to be a part of UC Launch, a highly selective accelerator within the University of California universities. We are one of 20 out of hundreds of applications that got chosen!
"LAUNCH is the University of California’s leading accelerator, designed to transform early-stage startups into fundable companies."
During Fall 2022, over 160+ companies raised over $725 million cumulatively. We look forward to growing and developing further through this program.
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the Makani Science offering. Here's an excerpt describing the specifics of the change:
Campaign is extending their end date by 30 days
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
Take a look at these 3 important facts about breathing!
One of our goals at Makani Science is to make sedation procedures safer. There is no doubt that medicine has improved greatly in the last couple of decades. However, there are still ways procedures could be made safer. Here’s an in-depth investigation Dallas Morning News published about safety concerns in the dental area: https://interactives.dallasnews.com/2015/deadly-dentistry/
We hope our breathing monitor can address some of these concerns!
This is Michael Chu, CEO of Makani Science. I wanted to thank everyone for their continued support and, introduce myself in this update. I am originally from northern California but after graduating from UC San Diego with a degree in Bioengineering and getting my doctoral degree at UC Irvine, I am enjoying life in southern California. I am a co-inventor and one of the original founders of Makani Science. Most importantly I just got married this past year!
As the CEO for Makani Science, these are the values I approach the company with every day:
• I believe in teamwork and respect – the team is key to the success of the company.
• Evidence-based science is important – data is key to showing that our product works.
• I believe in earning the trust of our employees, customers, and investors - Trust is hard to earn and I strive to be a company of integrity.
I understand investing your hard-earned money into a startup can be a difficult choice, so please ask any questions you may have to help make the decision easier. My team and I are here to make sure you make the most informed decision possible.
I truly appreciate your support and time and please stay safe and healthy!
Check out this link on how breathing can reduce stress!
Hi Everyone! I wanted to highlight the novel postage-size sensor used in our system.
Instead of being rigid and hard, (like a circuit board) our sensors are soft and elastic, like a rubber band. This will make the sensor much more comfortable to wear and expands the market opportunity into other previously untapped fields.
Share this with someone who would be interested in a new type of sensor!
Our early bird special is about to expire in less than 5 days.
Take advantage of it now and get bonus shares!
Did you know? Makani Science has been part of a number of well-known accelerators, such as Medtech Innovator and Y combinator. Y Combinator has housed well-known companies such as Airbnb. Medtech Innovator is the largest accelerator of medical technology in the world.
Buy Shares and invest in Makani Science!
Members get an extra 10% shares in addition to rewards below!
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
Tier 1 Perk
Invest $500+ and receive 2% bonus shares
Tier 2 Perk
Invest $1000+ and receive 5% bonus shares
Tier 3 Perk
Invest $5,000+ and receive 10% bonus shares
Tier 4 Perk
Invest $10,000+ and receive 15% bonus shares
Tier 5 Perk
Invest $20,000+ and receive 20% bonus shares
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.